Published in J Psychiatry Neurosci on July 01, 2004
5-HT(1A) receptor function in major depressive disorder. Prog Neurobiol (2009) 1.99
Genetic variation in cortico-amygdala serotonin function and risk for stress-related disease. Neurosci Biobehav Rev (2008) 1.65
Striatal dopamine D2/3 receptor availability in treatment resistant depression. PLoS One (2014) 1.44
CRF receptor 1 regulates anxiety behavior via sensitization of 5-HT2 receptor signaling. Nat Neurosci (2010) 1.38
RGS inhibition at G(alpha)i2 selectively potentiates 5-HT1A-mediated antidepressant effects. Proc Natl Acad Sci U S A (2010) 1.19
Serotonin-prefrontal cortical circuitry in anxiety and depression phenotypes: pivotal role of pre- and post-synaptic 5-HT1A receptor expression. Front Behav Neurosci (2014) 1.12
Transcriptional regulation of the 5-HT1A receptor: implications for mental illness. Philos Trans R Soc Lond B Biol Sci (2012) 1.10
Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs. Neurotherapeutics (2009) 1.10
Serotonin evokes endocannabinoid release and retrogradely suppresses excitatory synapses. J Neurosci (2008) 1.08
Serotonin transporters: implications for antidepressant drug development. AAPS J (2005) 1.02
F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia. Br J Pharmacol (2007) 0.99
Serotonin 5-HT2A and 5-HT6 receptors in the prefrontal cortex of Alzheimer and normal aging patients. BMC Neurosci (2006) 0.97
Enhanced function of prefrontal serotonin 5-HT(2) receptors in a rat model of psychiatric vulnerability. J Neurosci (2010) 0.96
An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression. Prim Care Companion J Clin Psychiatry (2006) 0.93
Interactome mapping of the phosphatidylinositol 3-kinase-mammalian target of rapamycin pathway identifies deformed epidermal autoregulatory factor-1 as a new glycogen synthase kinase-3 interactor. Mol Cell Proteomics (2010) 0.92
Fluoxetine (prozac) and serotonin act on excitatory synaptic transmission to suppress single layer 2/3 pyramidal neuron-triggered cell assemblies in the human prefrontal cortex. J Neurosci (2012) 0.91
Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist. Br J Pharmacol (2009) 0.91
F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profile. Br J Pharmacol (2007) 0.90
Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists. ACS Chem Neurosci (2014) 0.89
Sexually dimorphic serotonergic dysfunction in a mouse model of Huntington's disease and depression. PLoS One (2011) 0.89
Synaptic abnormalities in the infralimbic cortex of a model of congenital depression. J Neurosci (2013) 0.89
Neuropsychopharmacology and neurogenetic aspects of executive functioning: should reward gene polymorphisms constitute a diagnostic tool to identify individuals at risk for impaired judgment? Mol Neurobiol (2012) 0.88
Neuroendocrine immunoregulation in multiple sclerosis. Clin Dev Immunol (2013) 0.87
A genetic rat model of depression, Flinders sensitive line, has a lower density of 5-HT(1A) receptors, but a higher density of 5-HT(1B) receptors, compared to control rats. Neurochem Int (2008) 0.87
5-HT2A receptors in the orbitofrontal cortex facilitate reversal learning and contribute to the beneficial cognitive effects of chronic citalopram treatment in rats. Int J Neuropsychopharmacol (2011) 0.86
Pre-gestational stress reduces the ratio of 5-HIAA to 5-HT and the expression of 5-HT1A receptor and serotonin transporter in the brain of foetal rat. BMC Neurosci (2012) 0.85
Differential effects of serotonin 5-HT1A receptor agonists on the discriminative stimulus effects of the 5-HT2A receptor agonist 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane in rats and rhesus monkeys. J Pharmacol Exp Ther (2010) 0.85
Rapid desensitization of somatodendritic 5-HT1A receptors by chronic administration of the high-efficacy 5-HT1A agonist, F13714: a microdialysis study in the rat. Br J Pharmacol (2006) 0.85
Serotonin-2C and -2a receptor co-expression on cells in the rat medial prefrontal cortex. Neuroscience (2015) 0.84
Effects of sustained administration of quetiapine alone and in combination with a serotonin reuptake inhibitor on norepinephrine and serotonin transmission. Neuropsychopharmacology (2012) 0.84
Anxiety, Depression, and Somatic Distress: Developing a Transdiagnostic Internalizing Toolbox for Pediatric Practice. Cogn Behav Pract (2012) 0.84
Effects of serotonin (5-HT)1A and 5-HT2A receptor agonists on schedule-controlled responding in rats: drug combination studies. Psychopharmacology (Berl) (2010) 0.83
Exercise benefits brain function: the monoamine connection. Brain Sci (2013) 0.83
Subchronic treatment with fluoxetine and ketanserin increases hippocampal brain-derived neurotrophic factor, β-catenin and antidepressant-like effects. Br J Pharmacol (2012) 0.83
Neurobiological mechanisms of repetitive transcranial magnetic stimulation on the underlying neurocircuitry in unipolar depression. Dialogues Clin Neurosci (2011) 0.82
Systemic inflammation alters central 5-HT function as determined by pharmacological MRI. Neuroimage (2013) 0.82
Subanesthetic doses of ketamine transiently decrease serotonin transporter activity: a PET study in conscious monkeys. Neuropsychopharmacology (2013) 0.82
Cerebral 5-HT2A receptor binding, but not mGluR2, is increased in tryptophan hydroxylase 2 decrease-of-function mice. Neurosci Lett (2013) 0.81
Vilazodone for the treatment of major depressive disorder: focusing on its clinical studies and mechanism of action. Psychiatry Investig (2015) 0.81
Presynaptic selectivity of a ligand for serotonin 1A receptors revealed by in vivo PET assays of rat brain. PLoS One (2012) 0.81
Restricted access to standard or high fat chow alters sensitivity of rats to the 5-HT(2A/2C) receptor agonist 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane. Behav Pharmacol (2014) 0.81
Cannabinoid-induced enhanced interaction and protein levels of serotonin 5-HT(2A) and dopamine D₂ receptors in rat prefrontal cortex. J Psychopharmacol (2012) 0.81
Opposing local effects of endocannabinoids on the activity of noradrenergic neurons and release of noradrenaline: relevance for their role in depression and in the actions of CB(1) receptor antagonists. J Neural Transm (Vienna) (2012) 0.80
A review of vilazodone, serotonin, and major depressive disorder. Prim Care Companion CNS Disord (2014) 0.80
Fibroblast growth factor 8 deficiency compromises the functional response of the serotonergic system to stress. PLoS One (2014) 0.79
Assessing the neuronal serotonergic target-based antidepressant stratagem: impact of in vivo interaction studies and knockout models. Curr Neuropharmacol (2008) 0.79
Depression-like deficits in rats improved by subchronic modafinil. Psychopharmacology (Berl) (2009) 0.78
Diabetes-associated depression: the serotonergic system as a novel multifunctional target. Indian J Pharmacol (2015) 0.77
Sex dependent reduction by prenatal stress of the expression of 5HT1A receptors in the prefrontal cortex and CRF type 2 receptors in the raphe nucleus in rats: reversal by citalopram. Psychopharmacology (Berl) (2014) 0.77
Facilitation of serotonin signaling by SSRIs is attenuated by social isolation. Neuropsychopharmacology (2014) 0.77
Combination/augmentation strategies for improving the treatment of depression. Neuropsychiatr Dis Treat (2005) 0.77
Estrogen receptor β deficiency impairs BDNF-5-HT2A signaling in the hippocampus of female brain: A possible mechanism for menopausal depression. Psychoneuroendocrinology (2017) 0.77
Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation. Psychopharmacology (Berl) (2017) 0.76
Association between HTR2A T102C polymorphism and major depressive disorder: a meta-analysis in the Chinese population. Int J Clin Exp Med (2015) 0.76
Vilazodone for the Treatment of Depression: An Update. Chonnam Med J (2016) 0.76
Recurrence of suicidal ideation due to treatment with antidepressants in anxiety disorder: a case report. J Med Case Rep (2007) 0.75
DNA methylation in a Scottish family multiply affected by bipolar disorder and major depressive disorder. Clin Epigenetics (2016) 0.75
5-HT2A receptor antagonist M100907 reduces serotonin synthesis: an autoradiographic study. Brain Res Bull (2011) 0.75
5-HT1A Agonist Properties Contribute to a Robust Response to Vilazodone in the Novelty Suppressed Feeding Paradigm. Int J Neuropsychopharmacol (2016) 0.75
Neurobiology of severe mental disorders: from cell to bedside 25th International Symposium of the Centre de recherche en sciences neurologiques, Université de Montréal. J Psychiatry Neurosci (2004) 0.75
Towards a Functional Understanding of PGO Waves. Front Hum Neurosci (2017) 0.75
Involvement of diazepam-insensitive benzodiazepine receptors in the suppression of DOI-induced head-twitch responses in diabetic mice. Psychopharmacology (Berl) (2006) 0.75
Treating major depression with yoga: A prospective, randomized, controlled pilot trial. PLoS One (2017) 0.75
The stimulus effects of 8-OH-DPAT: evidence for a 5-HT2A receptor-mediated component. Pharmacol Biochem Behav (2007) 0.75
Understanding the Role of GPCR Heteroreceptor Complexes in Modulating the Brain Networks in Health and Disease. Front Cell Neurosci (2017) 0.75
Blonanserin - A Novel Antianxiety and Antidepressant Drug? An Experimental Study. J Clin Diagn Res (2016) 0.75
Distressing Visual Hallucinations after Treatment with Trazodone. Case Rep Psychiatry (2017) 0.75
ERβ and ApoE isoforms interact to regulate BDNF-5-HT2A signaling and synaptic function in the female brain. Alzheimers Res Ther (2017) 0.75
Serotonin and brain function: a tale of two receptors. J Psychopharmacol (2017) 0.75
Observational study to calculate addictive risk to opioids: a validation study of a predictive algorithm to evaluate opioid use disorder. Pharmgenomics Pers Med (2017) 0.75
Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet (1997) 44.03
An integrative theory of prefrontal cortex function. Annu Rev Neurosci (2001) 36.82
Neurobiology of depression. Neuron (2002) 8.56
A review of central 5-HT receptors and their function. Neuropharmacology (1999) 6.13
Structure and function of the brain serotonin system. Physiol Rev (1992) 5.30
Topographical organization of the efferent projections of the medial prefrontal cortex in the rat: an anterograde tract-tracing study with Phaseolus vulgaris leucoagglutinin. J Comp Neurol (1989) 4.96
Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol (2001) 4.00
Current advances and trends in the treatment of depression. Trends Pharmacol Sci (1994) 3.49
Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A (1996) 3.28
A G protein couples serotonin and GABAB receptors to the same channels in hippocampus. Science (1986) 3.17
Altered editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims. Neuron (2002) 3.06
Projections from the rat prefrontal cortex to the ventral tegmental area: target specificity in the synaptic associations with mesoaccumbens and mesocortical neurons. J Neurosci (2000) 2.91
Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res (1985) 2.68
Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch Gen Psychiatry (1989) 2.67
5-HT and antidepressants: new views from microdialysis studies. Trends Pharmacol Sci (1993) 2.65
An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. J Comp Neurol (1978) 2.63
Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry (1994) 2.54
Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice. Proc Natl Acad Sci U S A (1998) 2.27
Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry (2000) 2.25
Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci (1996) 2.22
Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors. Brain Res Mol Brain Res (1994) 2.21
Electrophysiological responses of serotoninergic dorsal raphe neurons to 5-HT1A and 5-HT1B agonists. Synapse (1987) 2.20
A novel augmentation strategy for treating resistant major depression. Am J Psychiatry (2001) 2.05
Increased anxiety of mice lacking the serotonin1A receptor. Proc Natl Acad Sci U S A (1998) 1.97
Control of dorsal raphe serotonergic neurons by the medial prefrontal cortex: Involvement of serotonin-1A, GABA(A), and glutamate receptors. J Neurosci (2001) 1.92
How does pindolol improve antidepressant action? Trends Pharmacol Sci (2001) 1.91
Forebrain afferents to the rat dorsal raphe nucleus demonstrated by retrograde and anterograde tracing methods. Neuroscience (1998) 1.90
5-Hydroxytryptamine2 and 5-hydroxytryptamine 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience (1991) 1.78
Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry (2003) 1.76
Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding. J Neurosci (1992) 1.76
Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. Br J Pharmacol (1999) 1.67
Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology (1997) 1.67
Mood disorders in stroke patients. Importance of location of lesion. Brain (1984) 1.62
5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc Natl Acad Sci U S A (1998) 1.61
The prefrontal cortex and the integration of sensory, limbic and autonomic information. Prog Brain Res (2000) 1.61
Combined administration of a 5-hydroxytryptamine (5-HT)1D antagonist and a 5-HT reuptake inhibitor synergistically increases 5-HT release in guinea pig hypothalamus in vivo. J Neurochem (1996) 1.57
Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors. J Neurosci (1998) 1.56
Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Res Bull (2001) 1.53
The role of serotonin in antipsychotic drug action. Neuropsychopharmacology (1999) 1.49
Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex. Cereb Cortex (2004) 1.48
An electrophysiological and neuroanatomical study of the medial prefrontal cortical projection to the midbrain raphe nuclei in the rat. Neuroscience (1998) 1.47
Activation of serotonin receptors modulates synaptic transmission in rat cerebral cortex. J Neurophysiol (1999) 1.45
5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem (2001) 1.43
Modification of 5-HT neuron properties by sustained administration of the 5-HT1A agonist gepirone: electrophysiological studies in the rat brain. Synapse (1987) 1.39
Prefrontal cortex regulates burst firing and transmitter release in rat mesolimbic dopamine neurons studied in vivo. Neurosci Lett (1993) 1.39
Immunocytochemical localization of serotonin1A receptors in the rat central nervous system. J Comp Neurol (1996) 1.39
Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse (1997) 1.38
Potent excitatory influence of prefrontal cortex activity on noradrenergic locus coeruleus neurons. Neuroscience (1998) 1.38
Origin and functional role of the extracellular serotonin in the midbrain raphe nuclei. Brain Res Brain Res Rev (2002) 1.30
Evidence for a role of GABA interneurones in the cortical modulation of midbrain 5-hydroxytryptamine neurones. Neuroscience (2001) 1.30
Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism. J Neurosci (2001) 1.29
Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex. Brain Res (1992) 1.26
The physiological role of 5-HT2A receptors in working memory. J Neurosci (2002) 1.23
Segregation of serotonin 5-HT2A and 5-HT3 receptors in inhibitory circuits of the primate cerebral cortex. J Comp Neurol (2000) 1.22
Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry (1999) 1.22
Ultrastructural localization of serotonin2A receptors in the middle layers of the rat prelimbic prefrontal cortex. Neuroscience (2003) 1.21
Efferent projections of the infralimbic (area 25) region of the medial prefrontal cortex in the rat: an anterograde tracer PHA-L study. Brain Res (1991) 1.20
The monoamine innervation of rat cerebral cortex: synaptic and nonsynaptic axon terminals. Neuroscience (1978) 1.19
Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Res (1999) 1.19
Differential effects of clomipramine given locally or systemically on extracellular 5-hydroxytryptamine in raphe nuclei and frontal cortex. An in vivo brain microdialysis study. Naunyn Schmiedebergs Arch Pharmacol (1991) 1.15
A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex. Neuroscience (2001) 1.14
Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group. J Affect Disord (1990) 1.13
Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study. Eur J Pharmacol (1992) 1.12
In vivo modulation of the activity of pyramidal neurons in the rat medial prefrontal cortex by 5-HT2A receptors: relationship to thalamocortical afferents. Cereb Cortex (2003) 1.12
Habenular and other midbrain raphe afferents demonstrated by a modified retrograde tracing technique. Brain Res (1977) 1.09
Modulation of the activity of pyramidal neurons in rat prefrontal cortex by raphe stimulation in vivo: involvement of serotonin and GABA. Cereb Cortex (2004) 1.09
Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Danish University Antidepressant Group. Psychopharmacology (Berl) (1986) 1.08
A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry (2002) 1.08
Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology (2002) 1.08
Neurochemical and electrophysiological studies on the functional significance of burst firing in serotonergic neurons. Neuroscience (2000) 1.06
Differential occupancy of somatodendritic and postsynaptic 5HT(1A) receptors by pindolol: a dose-occupancy study with [11C]WAY 100635 and positron emission tomography in humans. Neuropsychopharmacology (2001) 1.04
Actions of 5-hydroxytryptamine on neurons of the rat cingulate cortex. J Neurophysiol (1993) 1.03
Postmortem findings in suicide victims. Implications for in vivo imaging studies. Ann N Y Acad Sci (1997) 1.02
The molecular biology of serotonin receptors: therapeutic implications for the interface of mood and psychosis. Biol Psychiatry (1998) 1.02
Correspondence between 5-HT2 receptors and serotonergic axons in rat neocortex. Brain Res (1988) 1.02
Effect of pindolol on the function of pre- and postsynaptic 5-HT1A receptors: in vivo microdialysis and electrophysiological studies in the rat brain. Neuropsychopharmacology (1996) 1.01
Serotonin 5-HT1A receptors regulate AMPA receptor channels through inhibiting Ca2+/calmodulin-dependent kinase II in prefrontal cortical pyramidal neurons. J Biol Chem (2002) 1.00
Effects of acute fluoxetine on extracellular serotonin levels in the raphe: an in vivo microdialysis study. Eur J Pharmacol (1995) 0.99
Chronic fluoxetine treatment upregulates 5-HT uptake sites and 5-HT2 receptors in rat brain: an autoradiographic study. Synapse (1993) 0.98
Quantified distribution of the serotonin innervation in adult rat hippocampus. Neuroscience (1990) 0.98
The role of 5-HT1B receptors in the regulation of serotonin cell firing and release in the rat brain. J Neurochem (2001) 0.97
The effect of the selective 5-HT1A agonists alnespirone (S-20499) and 8-OH-DPAT on extracellular 5-hydroxytryptamine in different regions of rat brain. Br J Pharmacol (1997) 0.94
Pyramidal cell axons show a local specialization for GABA and 5-HT inputs in monkey and human cerebral cortex. J Comp Neurol (2001) 0.93
Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors. J Clin Psychopharmacol (2001) 0.92
Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse (1993) 0.92
Mitchell B. Balter Award--1998. Pindolol and major affective disorders: a three-year follow-up study of 30,485 patients. J Clin Psychopharmacol (1999) 0.91
Relationships of 5-hydroxytryptamine immunoreactive terminal-like varicosities to 5-hydroxytryptamine-2A receptor-immunoreactive neuronal processes in the rat forebrain. J Chem Neuroanat (2001) 0.90
A pre- and postsynaptic modulatory action of 5-HT and the 5-HT2A, 2C receptor agonist DOB on NMDA-evoked responses in the rat medial prefrontal cortex. Eur J Neurosci (1999) 0.89
Effect of fluoxetine on extracellular 5-hydroxytryptamine in rat brain. Role of 5-HT autoreceptors. Eur J Pharmacol (1998) 0.87
Inhibition of in vitro and ex vivo uptake of noradrenaline and 5-hydroxytryptamine by five antidepressants; correlation with reduction of spontaneous firing rate of central monoaminergic neurones. Naunyn Schmiedebergs Arch Pharmacol (1982) 0.86
Role of uptake inhibition and autoreceptor activation in the control of 5-HT release in the frontal cortex and dorsal hippocampus of the rat. Br J Pharmacol (2000) 0.86
Affinity of (+/-)-pindolol, (-)-penbutolol, and (-)-tertatolol for pre- and postsynaptic serotonin 5-HT(1A) receptors in human and rat brain. J Neurochem (2000) 0.86
Electrophysiological evidence for a functional interaction between 5-HT1A and 5-HT2A receptors in the rat medial prefrontal cortex: an iontophoretic study. Synapse (1994) 0.86
Electrophysiological characterization of 5-hydroxytryptamine2 receptors in the rat medial prefrontal cortex. J Pharmacol Exp Ther (1990) 0.85
BIMT 17, a 5-HT1A receptor agonist/5-HT2A receptor antagonist, directly activates postsynaptic 5-HT inhibitory responses in the rat cerebral cortex. Naunyn Schmiedebergs Arch Pharmacol (1995) 0.84
Differential effects of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) on various 5-HT receptor binding sites in the rat brain. Neuropharmacology (1994) 0.83
The 5-HT1A antagonist, WAY 100 635, alleviates cognitive impairments induced by dizocilpine (MK-801) in monkeys. Neuropharmacology (2000) 0.83
beta-blocker binding to human 5-HT(1A) receptors in vivo and in vitro: implications for antidepressant therapy. Neuropsychopharmacology (2000) 0.83
High 5HT2A receptor occupancy in M100907-treated schizophrenic patients. Psychopharmacology (Berl) (2000) 0.82
Effect of flow-stop on noradrenaline release from normal spleens and spleens treated with cocaine, phentolamine or phenoxybenzamine. Br J Pharmacol (1971) 3.33
Viral pollution in the environment and in shellfish: human adenovirus detection by PCR as an index of human viruses. Appl Environ Microbiol (1998) 2.51
Molecular characterization of two natural hotspots in the Drosophila buzzatii genome induced by transposon insertions. Genome Res (2001) 1.98
Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression. J Clin Psychiatry (2010) 1.55
Modification of the evoked release of noradrenaline from the perfused cat spleen by various ions and agents. J Physiol (1972) 1.54
Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex. Cereb Cortex (2004) 1.48
Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex (2004) 1.43
Is diabetic ketoacidosis a cause of meningeal syndrome? Case report. Diabetes Care (1998) 1.39
A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol (2011) 1.32
The somatodendritic release of dopamine in the ventral tegmental area and its regulation by afferent transmitter systems. Neurosci Biobehav Rev (2004) 1.32
Origin and functional role of the extracellular serotonin in the midbrain raphe nuclei. Brain Res Brain Res Rev (2002) 1.30
Influence of different upper age limits on the "Years of Potential Life Lost" index. Eur J Epidemiol (1992) 1.29
Quantitative analysis of the expression of dopamine D1 and D2 receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex (2008) 1.26
Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine. Proc Natl Acad Sci U S A (2007) 1.23
Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. Neuropsychopharmacology (2007) 1.19
Serotonin modulation of cortical neurons and networks. Front Integr Neurosci (2013) 1.15
In vivo modulation of the activity of pyramidal neurons in the rat medial prefrontal cortex by 5-HT2A receptors: relationship to thalamocortical afferents. Cereb Cortex (2003) 1.12
In vivo excitation of GABA interneurons in the medial prefrontal cortex through 5-HT3 receptors. Cereb Cortex (2004) 1.11
Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci (2005) 1.10
Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. CNS Drugs (2013) 1.10
Brain-derived neurotrophic factor modulates dopaminergic deficits in a transgenic mouse model of Huntington's disease. J Neurochem (2005) 1.09
Modulation of the activity of pyramidal neurons in rat prefrontal cortex by raphe stimulation in vivo: involvement of serotonin and GABA. Cereb Cortex (2004) 1.09
The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine. Neuropsychopharmacology (2005) 1.06
Technetium-99m-methoxyisobutylisonitrile in localization of ectopic parathyroid adenoma. J Nucl Med (1996) 1.06
Activation of thalamocortical networks by the N-methyl-D-aspartate receptor antagonist phencyclidine: reversal by clozapine. Biol Psychiatry (2011) 1.05
The hallucinogen DOI reduces low-frequency oscillations in rat prefrontal cortex: reversal by antipsychotic drugs. Biol Psychiatry (2008) 1.05
[Sedation in digestive endoscopy. Results of a hospital survey in Catalonia (Spain)]. Gastroenterol Hepatol (2004) 1.04
Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice. EMBO J (2007) 1.04
Strategies for producing faster acting antidepressants. Drug Discov Today (2005) 1.02
Acute 5-HT₁A autoreceptor knockdown increases antidepressant responses and serotonin release in stressful conditions. Psychopharmacology (Berl) (2012) 1.01
The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity. J Neurochem (2005) 0.98
Pyramidal neurons in rat prefrontal cortex projecting to ventral tegmental area and dorsal raphe nucleus express 5-HT2A receptors. Cereb Cortex (2008) 0.98
Regulation of cAMP phosphodiesterase mRNAs expression in rat brain by acute and chronic fluoxetine treatment. An in situ hybridization study. Neuropharmacology (2002) 0.95
5-HT1A receptor agonists enhance pyramidal cell firing in prefrontal cortex through a preferential action on GABA interneurons. Cereb Cortex (2011) 0.92
Selective enhancement of mesocortical dopaminergic transmission by noradrenergic drugs: therapeutic opportunities in schizophrenia. Int J Neuropsychopharmacol (2010) 0.90
Tuberculous pulmonary gangrene: report of a case and review. Clin Infect Dis (1994) 0.90
5-HT(2A) receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: a PET study. Psychopharmacology (Berl) (2003) 0.88
Pindolol augmentation of antidepressant response. Curr Drug Targets (2006) 0.88
Control of the serotonergic system by the medial prefrontal cortex: potential role in the etiology of PTSD and depressive disorders. Neurotox Res (2003) 0.87
Expression of parvalbumin and glutamic acid decarboxylase-67 after acute administration of MK-801. Implications for the NMDA hypofunction model of schizophrenia. Psychopharmacology (Berl) (2011) 0.86
Dopamine neurotransmission and atypical antipsychotics in prefrontal cortex: a critical review. Curr Top Med Chem (2012) 0.86
Nocardia otitidiscaviarum (GAM-5) induces parkinsonian-like alterations in mouse. Braz J Med Biol Res (2004) 0.86
GABAB receptor mRNA in the raphe nuclei: co-expression with serotonin transporter and glutamic acid decarboxylase. J Neurochem (2003) 0.86
Reactogenicity and antigenicity of rhesus rotavirus vaccine (MMU-18006) in newborn infants in Venezuela. Pediatr Infect Dis J (1988) 0.86
Ehlers-Danlos syndrome and periventricular nodular heterotopia in a Spanish family with a single FLNA mutation. J Med Genet (2005) 0.85
Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT(1A) receptors but not 5-HT(2A) receptors. Int J Neuropsychopharmacol (2010) 0.85
Clozapine Reverses Phencyclidine-Induced Desynchronization of Prefrontal Cortex through a 5-HT(1A) Receptor-Dependent Mechanism. Neuropsychopharmacology (2011) 0.85
Role of different monoamine receptors controlling MK-801-induced release of serotonin and glutamate in the medial prefrontal cortex: relevance for antipsychotic action. Int J Neuropsychopharmacol (2008) 0.84
In vivo efflux of serotonin in the dorsal raphe nucleus of 5-HT1A receptor knockout mice. J Neurochem (2004) 0.84
Outer membrane permeability of non-typable Haemophilus influenzae. J Antimicrob Chemother (1996) 0.84
Reversible inhibition of ACTH-induced corticosteroid release by cycloheximide: evidence for an unidentified cellular messenger. Endocrinology (1973) 0.84
Clozapine and olanzapine, but not haloperidol, suppress serotonin efflux in the medial prefrontal cortex elicited by phencyclidine and ketamine. Int J Neuropsychopharmacol (2005) 0.84
Clozapine does not require 5-HT1A receptors to block the locomotor hyperactivity induced by MK-801 Clz and MK-801 in KO1A mice. Neuropharmacology (2010) 0.83
Certain forms of matrix metalloproteinase-9 accumulate in the extracellular space after microdialysis probe implantation and middle cerebral artery occlusion/reperfusion. J Cereb Blood Flow Metab (2002) 0.83
Noradrenergic antidepressants increase cortical dopamine: potential use in augmentation strategies. Neuropharmacology (2012) 0.83
In vitro and in vivo activation of astrocytes by amyloid-beta is potentiated by pro-oxidant agents. J Alzheimers Dis (2010) 0.82
Unraveling monoamine receptors involved in the action of typical and atypical antipsychotics on glutamatergic and serotonergic transmission in prefrontal cortex. Curr Pharm Des (2010) 0.82
Feasibility of international data collection and feedback on post-operative pain data: proof of concept. Eur J Pain (2011) 0.82
Inhibitory effect of low pH on norepinephrine release. J Pharmacol Exp Ther (1971) 0.82
Catecholamine/Serotonin interactions: systems thinking for brain function and disease. Adv Pharmacol (2013) 0.82
Simultaneous projections from prefrontal cortex to dopaminergic and serotonergic nuclei. Int J Neuropsychopharmacol (2010) 0.82
NMDA antagonist and antipsychotic actions in cortico-subcortical circuits. Neurotox Res (2008) 0.81
Importance of inter-hemispheric prefrontal connection in the effects of non-competitive NMDA receptor antagonists. Int J Neuropsychopharmacol (2011) 0.81
An autoradiographic study of the influence of pindolol upon [35S]GTPgammaS binding in rat, guinea pig and human brain. Int J Neuropsychopharmacol (2004) 0.81
Activation of pyramidal cells in rat medial prefrontal cortex projecting to ventral tegmental area by a 5-HT1A receptor agonist. Eur Neuropsychopharmacol (2005) 0.81
In vivo modulation of 5-hydroxytryptamine release in mouse prefrontal cortex by local 5-HT(2A) receptors: effect of antipsychotic drugs. Eur J Neurosci (2003) 0.80
Efficacy of augmented immunosuppressive therapy for early vasculopathy in heart transplantation. J Am Coll Cardiol (1998) 0.80
Disruption of thalamocortical activity in schizophrenia models: relevance to antipsychotic drug action. Int J Neuropsychopharmacol (2013) 0.80
Association between CCK-AR gene and schizophrenia with auditory hallucinations. Psychiatr Genet (2007) 0.80
Stimulation of alpha1-adrenoceptors in the rat medial prefrontal cortex increases the local in vivo 5-hydroxytryptamine release: reversal by antipsychotic drugs. J Neurochem (2003) 0.79
A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer. Invest New Drugs (2012) 0.79
Pindolol augmentation enhances response outcomes in first depressive episodes. Eur Neuropsychopharmacol (2009) 0.79
Disseminated cytomegalovirus infection in an immunocompetent adult successfully treated with ganciclovir. Scand J Infect Dis (1995) 0.79
Modulation of serotonergic function in rat brain by VN2222, a serotonin reuptake inhibitor and 5-HT1A receptor agonist. Neuropsychopharmacology (2002) 0.79
Evaluation of the protein quality of an isolated soy protein in young men: relative nitrogen requirements and effect of methionine supplementation. Am J Clin Nutr (1984) 0.78
In vivo electrophysiological and neurochemical effects of the selective 5-HT1A receptor agonist, F13640, at pre- and postsynaptic 5-HT1A receptors in the rat. Psychopharmacology (Berl) (2011) 0.78
Lipopolysaccharide recovery restores susceptibility levels towards beta-lactams in Serratia marcescens. Microbios (1995) 0.77
Somatostatin receptor scintigraphy predicts impending cardiac allograft rejection before endomyocardial biopsy. Eur J Nucl Med (2000) 0.77
Effect on the sympathetic nervous system of chronic treatment with pargyline and l-Dopa. J Pharmacol Exp Ther (1972) 0.77
The stereoisomers of 3,4-dihydroxyphenylserine as precursors of norepinephrine. J Pharmacol Exp Ther (1975) 0.77
Moraxella catarrhalis bacteraemia in an immunocompetent adult. Scand J Infect Dis (1995) 0.77
[Value of ultrasonography in the early diagnosis of hepatocellular carcinoma]. Rev Esp Enferm Dig (1993) 0.77
The absence of 5-HT(1A) receptors has minor effects on dopamine but not serotonin release evoked by MK-801 in mice prefrontal cortex. Psychopharmacology (Berl) (2008) 0.77
A functional leptin system is essential for sodium tungstate antiobesity action. Endocrinology (2008) 0.77
Mitotic arrest induced by fenvalerate in human lymphocyte cultures. Toxicol Lett (1989) 0.77
Determination of enrofloxacin and its primary metabolite, ciprofloxacin, in pig tissues. Application to residue studies. Biomed Chromatogr (2005) 0.77
Invasive pneumococcal disease in HIV-1 infected patients. Lancet (1996) 0.76